| Nuvation Bio Inc. |
Director |
Class A Common Stock |
17.1M |
$50.7M |
$2.97 |
Sep 4, 2024 |
By Decheng Anbio Limited |
| Nuvation Bio Inc. |
Director |
Class A Common Stock |
7.61M |
$22.6M |
$2.97 |
Sep 4, 2024 |
By Decheng Capital Global Healthcare Fund (Master), LP |
| Nuvation Bio Inc. |
Director |
Class A Common Stock |
1.28M |
$3.81M |
$2.97 |
Sep 4, 2024 |
By Decheng Capital China Life Sciences USD Fund III, L.P. |
| Cue Health Inc. |
Director |
Common Stock |
788K |
$237K |
$0.30 |
Sep 28, 2021 |
Indirect |
| ALPINE IMMUNE SCIENCES, INC. |
Director, 10%+ Owner |
Common Stock |
0 |
$0 |
$6.33 |
May 18, 2024 |
Indirect |
| Nuvation Bio Inc. |
Director |
Warrants (Right to Buy) |
438K |
|
|
Sep 3, 2024 |
By Decheng Anbio Limited |
| Nuvation Bio Inc. |
Director |
Warrants (Right to Buy) |
175K |
|
|
Sep 3, 2024 |
By Decheng Capital Global Healthcare Fund (Master), LP |
| Nuvation Bio Inc. |
Director |
Warrants (Right to Buy) |
32.9K |
|
|
Sep 3, 2024 |
By Decheng Capital China Life Sciences USD Fund III, L.P. |
| ALPINE IMMUNE SCIENCES, INC. |
Director, 10%+ Owner |
Stock Option (Right to buy) |
0 |
|
|
May 20, 2024 |
Direct |
| ALPINE IMMUNE SCIENCES, INC. |
Director, 10%+ Owner |
Warrant (right to buy) |
0 |
|
|
Jan 18, 2024 |
Indirect |
| Cue Health Inc. |
Director |
Series C-1 Preferred Stock |
0 |
|
|
Sep 28, 2021 |
Indirect |
| Nuvation Bio Inc. |
Director |
Series A Preferred Stock |
0 |
|
|
Sep 4, 2024 |
By Decheng Anbio Limited |
| Nuvation Bio Inc. |
Director |
Series A Preferred Stock |
0 |
|
|
Sep 4, 2024 |
By Decheng Capital China Life Sciences USD Fund III, L.P. |
| Nuvation Bio Inc. |
Director |
Series A Preferred Stock |
0 |
|
|
Sep 4, 2024 |
By Decheng Capital Global Healthcare Fund (Master), LP |